ID   TENA_HUMAN              Reviewed;        2201 AA.
AC   P24821; C9IYT7; C9J575; C9J6D9; C9J848; Q14583; Q15567; Q5T7S3;
DT   01-MAR-1992, integrated into UniProtKB/Swiss-Prot.
DT   15-DEC-2009, sequence version 3.
DT   28-JAN-2026, entry version 252.
DE   RecName: Full=Tenascin;
DE            Short=TN;
DE   AltName: Full=Cytotactin;
DE   AltName: Full=GMEM;
DE   AltName: Full=GP 150-225;
DE   AltName: Full=Glioma-associated-extracellular matrix antigen;
DE   AltName: Full=Hexabrachion;
DE   AltName: Full=JI;
DE   AltName: Full=Myotendinous antigen;
DE   AltName: Full=Neuronectin;
DE   AltName: Full=Tenascin-C;
DE            Short=TN-C;
DE   Flags: Precursor;
GN   Name=TNC; Synonyms=HXB;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANTS ARG-539; LEU-1677 AND
RP   GLN-2008.
RX   PubMed=1704365; DOI=10.1016/s0021-9258(18)49920-6;
RA   Nies D.E., Hemesath T.J., Kim J.H., Gulcher J.R., Stefansson K.;
RT   "The complete cDNA sequence of human hexabrachion (Tenascin). A multidomain
RT   protein containing unique epidermal growth factor repeats.";
RL   J. Biol. Chem. 266:2818-2823(1991).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1; 2; 4 AND 5), PROTEIN SEQUENCE OF
RP   23-32, AND VARIANTS ARG-680 AND GLN-2008.
RC   TISSUE=Fetal brain, and Melanoma;
RX   PubMed=1707164; DOI=10.1093/nar/19.3.525;
RA   Siri A., Carnemolla B., Saginati M., Leprini A., Casari G., Baralle F.,
RA   Zardi L.;
RT   "Human tenascin: primary structure, pre-mRNA splicing patterns and
RT   localization of the epitopes recognized by two monoclonal antibodies.";
RL   Nucleic Acids Res. 19:525-531(1991).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANTS ARG-539; LEU-1677 AND
RP   GLN-2008.
RX   PubMed=1719530; DOI=10.1073/pnas.88.21.9438;
RA   Gulcher J.R., Nies D.E., Alexakos M.J., Ravikant N.A., Sturgill M.E.,
RA   Marton L.S., Stefansson K.;
RT   "Structure of the human hexabrachion (tenascin) gene.";
RL   Proc. Natl. Acad. Sci. U.S.A. 88:9438-9442(1991).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANTS LEU-1677 AND GLN-2008.
RX   PubMed=7531707; DOI=10.1074/jbc.270.7.3429;
RA   Gherzi R., Carnemolla B., Siri A., Ponassi M., Balza E., Zardi L.;
RT   "Human tenascin gene. Structure of the 5'-region, identification, and
RT   characterization of the transcription regulatory sequences.";
RL   J. Biol. Chem. 270:3429-3434(1995).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15164053; DOI=10.1038/nature02465;
RA   Humphray S.J., Oliver K., Hunt A.R., Plumb R.W., Loveland J.E., Howe K.L.,
RA   Andrews T.D., Searle S., Hunt S.E., Scott C.E., Jones M.C., Ainscough R.,
RA   Almeida J.P., Ambrose K.D., Ashwell R.I.S., Babbage A.K., Babbage S.,
RA   Bagguley C.L., Bailey J., Banerjee R., Barker D.J., Barlow K.F., Bates K.,
RA   Beasley H., Beasley O., Bird C.P., Bray-Allen S., Brown A.J., Brown J.Y.,
RA   Burford D., Burrill W., Burton J., Carder C., Carter N.P., Chapman J.C.,
RA   Chen Y., Clarke G., Clark S.Y., Clee C.M., Clegg S., Collier R.E.,
RA   Corby N., Crosier M., Cummings A.T., Davies J., Dhami P., Dunn M.,
RA   Dutta I., Dyer L.W., Earthrowl M.E., Faulkner L., Fleming C.J.,
RA   Frankish A., Frankland J.A., French L., Fricker D.G., Garner P.,
RA   Garnett J., Ghori J., Gilbert J.G.R., Glison C., Grafham D.V., Gribble S.,
RA   Griffiths C., Griffiths-Jones S., Grocock R., Guy J., Hall R.E.,
RA   Hammond S., Harley J.L., Harrison E.S.I., Hart E.A., Heath P.D.,
RA   Henderson C.D., Hopkins B.L., Howard P.J., Howden P.J., Huckle E.,
RA   Johnson C., Johnson D., Joy A.A., Kay M., Keenan S., Kershaw J.K.,
RA   Kimberley A.M., King A., Knights A., Laird G.K., Langford C., Lawlor S.,
RA   Leongamornlert D.A., Leversha M., Lloyd C., Lloyd D.M., Lovell J.,
RA   Martin S., Mashreghi-Mohammadi M., Matthews L., McLaren S., McLay K.E.,
RA   McMurray A., Milne S., Nickerson T., Nisbett J., Nordsiek G., Pearce A.V.,
RA   Peck A.I., Porter K.M., Pandian R., Pelan S., Phillimore B., Povey S.,
RA   Ramsey Y., Rand V., Scharfe M., Sehra H.K., Shownkeen R., Sims S.K.,
RA   Skuce C.D., Smith M., Steward C.A., Swarbreck D., Sycamore N., Tester J.,
RA   Thorpe A., Tracey A., Tromans A., Thomas D.W., Wall M., Wallis J.M.,
RA   West A.P., Whitehead S.L., Willey D.L., Williams S.A., Wilming L.,
RA   Wray P.W., Young L., Ashurst J.L., Coulson A., Blocker H., Durbin R.M.,
RA   Sulston J.E., Hubbard T., Jackson M.J., Bentley D.R., Beck S., Rogers J.,
RA   Dunham I.;
RT   "DNA sequence and analysis of human chromosome 9.";
RL   Nature 429:369-374(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 46-125 (ISOFORMS 1/2/3/4/5/6).
RC   TISSUE=Fetal cartilage;
RX   PubMed=7524681; DOI=10.1016/0167-4781(94)90220-8;
RA   Glumoff V., Savontaus M., Vehanen J., Vuorio E.;
RT   "Analysis of aggrecan and tenascin gene expression in mouse skeletal
RT   tissues by northern and in situ hybridization using species specific cDNA
RT   probes.";
RL   Biochim. Biophys. Acta 1219:613-622(1994).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 431-2055 (ISOFORMS 1 AND 6), AND VARIANTS
RP   ARG-539; LEU-1677 AND GLN-2008.
RC   TISSUE=Glioblastoma;
RX   PubMed=2466295; DOI=10.1073/pnas.86.5.1588;
RA   Gulcher J.R., Nies D.E., Marton L.S., Stefansson K.;
RT   "An alternatively spliced region of the human hexabrachion contains a
RT   repeat of potential N-glycosylation sites.";
RL   Proc. Natl. Acad. Sci. U.S.A. 86:1588-1592(1989).
RN   [8]
RP   INTERACTION WITH CSPG4.
RX   PubMed=8824254; DOI=10.1074/jbc.271.42.26110;
RA   Burg M.A., Tillet E., Timpl R., Stallcup W.B.;
RT   "Binding of the NG2 proteoglycan to type VI collagen and other
RT   extracellular matrix molecules.";
RL   J. Biol. Chem. 271:26110-26116(1996).
RN   [9]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-1809.
RC   TISSUE=Plasma;
RX   PubMed=16335952; DOI=10.1021/pr0502065;
RA   Liu T., Qian W.-J., Gritsenko M.A., Camp D.G. II, Monroe M.E., Moore R.J.,
RA   Smith R.D.;
RT   "Human plasma N-glycoproteome analysis by immunoaffinity subtraction,
RT   hydrazide chemistry, and mass spectrometry.";
RL   J. Proteome Res. 4:2070-2080(2005).
RN   [10]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-184; ASN-1079; ASN-1093;
RP   ASN-1261; ASN-1301; ASN-1485 AND ASN-2162.
RC   TISSUE=Milk;
RX   PubMed=18780401; DOI=10.1002/pmic.200701057;
RA   Picariello G., Ferranti P., Mamone G., Roepstorff P., Addeo F.;
RT   "Identification of N-linked glycoproteins in human milk by hydrophilic
RT   interaction liquid chromatography and mass spectrometry.";
RL   Proteomics 8:3833-3847(2008).
RN   [11]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-1018; ASN-1034; ASN-1184;
RP   ASN-1275; ASN-1301; ASN-1366 AND ASN-1485.
RC   TISSUE=Liver;
RX   PubMed=19159218; DOI=10.1021/pr8008012;
RA   Chen R., Jiang X., Sun D., Han G., Wang F., Ye M., Wang L., Zou H.;
RT   "Glycoproteomics analysis of human liver tissue by combination of multiple
RT   enzyme digestion and hydrazide chemistry.";
RL   J. Proteome Res. 8:651-661(2009).
RN   [12]
RP   FUNCTION.
RX   PubMed=19884327; DOI=10.1096/fj.09-140491;
RA   Martina E., Degen M., Rueegg C., Merlo A., Lino M.M., Chiquet-Ehrismann R.,
RA   Brellier F.;
RT   "Tenascin-W is a specific marker of glioma-associated blood vessels and
RT   stimulates angiogenesis in vitro.";
RL   FASEB J. 24:778-787(2010).
RN   [13]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [14]
RP   INTERACTION WITH ITGA9:ITGB1.
RX   PubMed=22654117; DOI=10.1074/jbc.m112.355016;
RA   Sato-Nishiuchi R., Nakano I., Ozawa A., Sato Y., Takeichi M., Kiyozumi D.,
RA   Yamazaki K., Yasunaga T., Futaki S., Sekiguchi K.;
RT   "Polydom/SVEP1 is a ligand for integrin alpha9beta1.";
RL   J. Biol. Chem. 287:25615-25630(2012).
RN   [15]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-65; SER-70; SER-72 AND
RP   THR-905, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [16]
RP   PHOSPHORYLATION AT SER-72.
RX   PubMed=26091039; DOI=10.1016/j.cell.2015.05.028;
RA   Tagliabracci V.S., Wiley S.E., Guo X., Kinch L.N., Durrant E., Wen J.,
RA   Xiao J., Cui J., Nguyen K.B., Engel J.L., Coon J.J., Grishin N.,
RA   Pinna L.A., Pagliarini D.J., Dixon J.E.;
RT   "A single kinase generates the majority of the secreted phosphoproteome.";
RL   Cell 161:1619-1632(2015).
RN   [17]
RP   TISSUE SPECIFICITY, AND GLYCOSYLATION AT SER-72.
RX   PubMed=36213313; DOI=10.1007/s42485-022-00092-3;
RA   Ramarajan M.G., Saraswat M., Budhraja R., Garapati K., Raymond K.,
RA   Pandey A.;
RT   "Mass spectrometric analysis of chondroitin sulfate-linked peptides.";
RL   J. Proteins Proteom. 13:187-203(2022).
RN   [18]
RP   X-RAY CRYSTALLOGRAPHY (1.8 ANGSTROMS) OF FIBRONECTIN TYPE-III 3.
RX   PubMed=1279805; DOI=10.1126/science.1279805;
RA   Leahy D.J., Hendrickson W.A., Aukhil I., Erickson H.P.;
RT   "Structure of a fibronectin type III domain from tenascin phased by MAD
RT   analysis of the selenomethionyl protein.";
RL   Science 258:987-991(1992).
RN   [19]
RP   VARIANTS DFNA56 MET-1773 AND SER-1796.
RX   PubMed=23936043; DOI=10.1371/journal.pone.0069549;
RA   Zhao Y., Zhao F., Zong L., Zhang P., Guan L., Zhang J., Wang D., Wang J.,
RA   Chai W., Lan L., Li Q., Han B., Yang L., Jin X., Yang W., Hu X., Wang X.,
RA   Li N., Li Y., Petit C., Wang J., Wang H.Y., Wang Q.;
RT   "Exome sequencing and linkage analysis identified tenascin-C (TNC) as a
RT   novel causative gene in nonsyndromic hearing loss.";
RL   PLoS ONE 8:E69549-E69549(2013).
CC   -!- FUNCTION: Extracellular matrix protein implicated in guidance of
CC       migrating neurons as well as axons during development, synaptic
CC       plasticity as well as neuronal regeneration. Promotes neurite outgrowth
CC       from cortical neurons grown on a monolayer of astrocytes. Ligand for
CC       integrins alpha-8/beta-1, alpha-9/beta-1, alpha-V/beta-3 and alpha-
CC       V/beta-6. In tumors, stimulates angiogenesis by elongation, migration
CC       and sprouting of endothelial cells (PubMed:19884327).
CC       {ECO:0000269|PubMed:19884327}.
CC   -!- SUBUNIT: Homohexamer; disulfide-linked. A homotrimer may be formed in
CC       the triple coiled-coil region and may be stabilized by disulfide rings
CC       at both ends. Two of such half-hexabrachions may be disulfide linked
CC       within the central globule. Interacts with CSPG4 (PubMed:8824254).
CC       Interacts (via the 3rd fibronectin type-III domain) with integrin
CC       ITGA9:ITGB1 (PubMed:22654117). {ECO:0000269|PubMed:22654117,
CC       ECO:0000269|PubMed:8824254}.
CC   -!- INTERACTION:
CC       P24821; P20908: COL5A1; NbExp=2; IntAct=EBI-9979894, EBI-2464511;
CC       P24821; O00206: TLR4; NbExp=4; IntAct=EBI-9979894, EBI-528701;
CC   -!- SUBCELLULAR LOCATION: Secreted, extracellular space, extracellular
CC       matrix.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=6;
CC         Comment=Isoforms are produced in a tissue- and time-specific manner
CC         during development.;
CC       Name=1;
CC         IsoId=P24821-1; Sequence=Displayed;
CC       Name=2; Synonyms=HT-5;
CC         IsoId=P24821-2; Sequence=VSP_001412, VSP_001413;
CC       Name=3;
CC         IsoId=P24821-3; Sequence=VSP_001412;
CC       Name=4; Synonyms=HT-33;
CC         IsoId=P24821-4; Sequence=VSP_001413;
CC       Name=5;
CC         IsoId=P24821-5; Sequence=VSP_001414;
CC       Name=6; Synonyms=P31;
CC         IsoId=P24821-6; Sequence=VSP_001415;
CC   -!- TISSUE SPECIFICITY: Detected in fibroblasts (at protein level).
CC       {ECO:0000269|PubMed:36213313}.
CC   -!- DISEASE: Deafness, autosomal dominant, 56 (DFNA56) [MIM:615629]: A form
CC       of non-syndromic sensorineural hearing loss. Sensorineural deafness
CC       results from damage to the neural receptors of the inner ear, the nerve
CC       pathways to the brain, or the area of the brain that receives sound
CC       information. DFNA56 is characterized by progressive hearing impairment
CC       with postlingual onset. {ECO:0000269|PubMed:23936043}. Note=The disease
CC       is caused by variants affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the tenascin family. {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and
CC       Haematology;
CC       URL="https://atlasgeneticsoncology.org/gene/42597/TNC";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; M55618; AAA88083.1; -; mRNA.
DR   EMBL; X56160; CAA39628.1; -; mRNA.
DR   EMBL; X78565; CAA55309.1; -; mRNA.
DR   EMBL; AL162425; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; X80280; -; NOT_ANNOTATED_CDS; mRNA.
DR   EMBL; M24630; AAA52703.1; -; mRNA.
DR   CCDS; CCDS6811.1; -. [P24821-1]
DR   PIR; I38337; A32160.
DR   RefSeq; NP_001426004.1; NM_001439075.1. [P24821-1]
DR   RefSeq; NP_001426005.1; NM_001439076.1. [P24821-1]
DR   RefSeq; NP_001426006.1; NM_001439077.1. [P24821-4]
DR   RefSeq; NP_001426008.1; NM_001439079.1. [P24821-4]
DR   RefSeq; NP_001426019.1; NM_001439090.1. [P24821-3]
DR   RefSeq; NP_001426023.1; NM_001439094.1. [P24821-2]
DR   RefSeq; NP_001426025.1; NM_001439096.1. [P24821-5]
DR   RefSeq; NP_001426028.1; NM_001439099.1. [P24821-6]
DR   RefSeq; NP_001426029.1; NM_001439100.1. [P24821-6]
DR   RefSeq; NP_001426030.1; NM_001439101.1. [P24821-6]
DR   RefSeq; NP_002151.2; NM_002160.4. [P24821-1]
DR   RefSeq; XP_047279273.1; XM_047423317.1. [P24821-4]
DR   PDB; 1TEN; X-ray; 1.80 A; A=802-891.
DR   PDB; 2RB8; X-ray; 1.45 A; A=802-893.
DR   PDB; 2RBL; X-ray; 2.10 A; A/B/M=802-893.
DR   PDB; 5R5T; X-ray; 1.55 A; A=1979-2196.
DR   PDB; 5R5U; X-ray; 1.52 A; A=1979-2196.
DR   PDB; 5R5V; X-ray; 1.70 A; A=1979-2196.
DR   PDB; 5R5W; X-ray; 1.60 A; A=1979-2196.
DR   PDB; 5R5X; X-ray; 1.56 A; A=1979-2196.
DR   PDB; 5R5Y; X-ray; 1.57 A; A=1979-2196.
DR   PDB; 5R5Z; X-ray; 1.67 A; A=1979-2196.
DR   PDB; 5R60; X-ray; 1.79 A; A=1979-2196.
DR   PDB; 5R61; X-ray; 1.38 A; A=1979-2196.
DR   PDB; 5R62; X-ray; 1.40 A; A=1979-2196.
DR   PDB; 5R63; X-ray; 1.59 A; A=1979-2196.
DR   PDB; 6BRB; X-ray; 2.82 A; D=809-893.
DR   PDB; 6QNV; X-ray; 1.40 A; A=1979-2196.
DR   PDB; 8FN8; X-ray; 1.89 A; A=1975-2201.
DR   PDB; 8FNB; X-ray; 1.80 A; A/B=1975-2201.
DR   PDB; 9NIG; X-ray; 3.20 A; G/L/P=1013-1024.
DR   PDB; 9NIH; X-ray; 2.40 A; C=1013-1024.
DR   PDBsum; 1TEN; -.
DR   PDBsum; 2RB8; -.
DR   PDBsum; 2RBL; -.
DR   PDBsum; 5R5T; -.
DR   PDBsum; 5R5U; -.
DR   PDBsum; 5R5V; -.
DR   PDBsum; 5R5W; -.
DR   PDBsum; 5R5X; -.
DR   PDBsum; 5R5Y; -.
DR   PDBsum; 5R5Z; -.
DR   PDBsum; 5R60; -.
DR   PDBsum; 5R61; -.
DR   PDBsum; 5R62; -.
DR   PDBsum; 5R63; -.
DR   PDBsum; 6BRB; -.
DR   PDBsum; 6QNV; -.
DR   PDBsum; 8FN8; -.
DR   PDBsum; 8FNB; -.
DR   PDBsum; 9NIG; -.
DR   PDBsum; 9NIH; -.
DR   AlphaFoldDB; P24821; -.
DR   SMR; P24821; -.
DR   BioGRID; 109602; 28.
DR   ComplexPortal; CPX-466; Tenascin-C complex.
DR   CORUM; P24821; -.
DR   FunCoup; P24821; 615.
DR   IntAct; P24821; 14.
DR   MINT; P24821; -.
DR   STRING; 9606.ENSP00000265131; -.
DR   ChEMBL; CHEMBL3712856; -.
DR   UniLectin; P24821; -.
DR   GlyConnect; 1792; 72 N-Linked glycans (14 sites).
DR   GlyCosmos; P24821; 31 sites, 67 glycans.
DR   GlyGen; P24821; 32 sites, 200 N-linked glycans (15 sites), 2 O-linked glycans (8 sites).
DR   iPTMnet; P24821; -.
DR   PhosphoSitePlus; P24821; -.
DR   SwissPalm; P24821; -.
DR   BioMuta; TNC; -.
DR   DMDM; 281185495; -.
DR   CPTAC; non-CPTAC-2700; -.
DR   jPOST; P24821; -.
DR   MassIVE; P24821; -.
DR   PaxDb; 9606-ENSP00000265131; -.
DR   PeptideAtlas; P24821; -.
DR   ProteomicsDB; 54225; -. [P24821-1]
DR   ProteomicsDB; 54226; -. [P24821-2]
DR   ProteomicsDB; 54227; -. [P24821-3]
DR   ProteomicsDB; 54228; -. [P24821-4]
DR   ProteomicsDB; 54229; -. [P24821-5]
DR   ProteomicsDB; 54230; -. [P24821-6]
DR   Pumba; P24821; -.
DR   ABCD; P24821; 46 sequenced antibodies.
DR   Antibodypedia; 1348; 1053 antibodies from 44 providers.
DR   DNASU; 3371; -.
DR   Ensembl; ENST00000350763.9; ENSP00000265131.4; ENSG00000041982.18. [P24821-1]
DR   Ensembl; ENST00000537320.6; ENSP00000443478.1; ENSG00000041982.18. [P24821-6]
DR   GeneID; 3371; -.
DR   KEGG; hsa:3371; -.
DR   MANE-Select; ENST00000350763.9; ENSP00000265131.4; NM_002160.4; NP_002151.2.
DR   UCSC; uc004bjj.6; human. [P24821-1]
DR   AGR; HGNC:5318; -.
DR   CIViC; 3371; 2 evidence items across 1 molecular profile.
DR   ClinPGx; PA35103; -.
DR   CTD; 3371; -.
DR   DisGeNET; 3371; -.
DR   GeneCards; TNC; -.
DR   HGNC; HGNC:5318; TNC.
DR   HPA; ENSG00000041982; Tissue enhanced (lymphoid tissue, smooth muscle).
DR   MalaCards; TNC; -.
DR   MIM; 187380; gene.
DR   MIM; 615629; phenotype.
DR   OpenTargets; ENSG00000041982; -.
DR   Orphanet; 90635; Rare autosomal dominant non-syndromic sensorineural deafness type DFNA.
DR   VEuPathDB; HostDB:ENSG00000041982; -.
DR   eggNOG; KOG1225; Eukaryota.
DR   eggNOG; KOG2579; Eukaryota.
DR   GeneTree; ENSGT00940000155188; -.
DR   HOGENOM; CLU_001162_1_1_1; -.
DR   InParanoid; P24821; -.
DR   OMA; HHNGRCE; -.
DR   OrthoDB; 442731at2759; -.
DR   PAN-GO; P24821; 4 GO annotations based on evolutionary models.
DR   PhylomeDB; P24821; -.
DR   PathwayCommons; P24821; -.
DR   Reactome; R-HSA-216083; Integrin cell surface interactions.
DR   Reactome; R-HSA-3000170; Syndecan interactions.
DR   Reactome; R-HSA-3000178; ECM proteoglycans.
DR   Reactome; R-HSA-381426; Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs).
DR   Reactome; R-HSA-8957275; Post-translational protein phosphorylation.
DR   SignaLink; P24821; -.
DR   SIGNOR; P24821; -.
DR   Agora; ENSG00000041982; -.
DR   BioGRID-ORCS; 3371; 10 hits in 1156 CRISPR screens.
DR   CD-CODE; FB4E32DD; Presynaptic clusters and postsynaptic densities.
DR   ChiTaRS; TNC; human.
DR   EvolutionaryTrace; P24821; -.
DR   GeneWiki; Tenascin_C; -.
DR   GenomeRNAi; 3371; -.
DR   Pharos; P24821; Tbio.
DR   PRO; PR:P24821; -.
DR   Proteomes; UP000005640; Chromosome 9.
DR   RNAct; P24821; protein.
DR   Bgee; ENSG00000041982; Expressed in saphenous vein and 187 other cell types or tissues.
DR   ExpressionAtlas; P24821; baseline and differential.
DR   GO; GO:0005604; C:basement membrane; ISO:ComplexPortal.
DR   GO; GO:0005788; C:endoplasmic reticulum lumen; TAS:Reactome.
DR   GO; GO:0031012; C:extracellular matrix; IDA:ComplexPortal.
DR   GO; GO:0098965; C:extracellular matrix of synaptic cleft; IEA:Ensembl.
DR   GO; GO:0005576; C:extracellular region; HDA:BHF-UCL.
DR   GO; GO:0005615; C:extracellular space; HDA:UniProtKB.
DR   GO; GO:0005925; C:focal adhesion; HDA:UniProtKB.
DR   GO; GO:0098978; C:glutamatergic synapse; IEA:Ensembl.
DR   GO; GO:0005614; C:interstitial matrix; IEA:Ensembl.
DR   GO; GO:0016020; C:membrane; HDA:UniProtKB.
DR   GO; GO:0098966; C:perisynaptic extracellular matrix; IBA:GO_Central.
DR   GO; GO:0090733; C:tenascin complex; ISO:ComplexPortal.
DR   GO; GO:0005201; F:extracellular matrix structural constituent; ISS:BHF-UCL.
DR   GO; GO:0005178; F:integrin binding; IDA:UniProtKB.
DR   GO; GO:0045545; F:syndecan binding; IDA:MGI.
DR   GO; GO:0060447; P:bud outgrowth involved in lung branching; IEA:Ensembl.
DR   GO; GO:0007155; P:cell adhesion; TAS:ProtInc.
DR   GO; GO:0071799; P:cellular response to prostaglandin D stimulus; IEA:Ensembl.
DR   GO; GO:0071300; P:cellular response to retinoic acid; IEA:Ensembl.
DR   GO; GO:0071305; P:cellular response to vitamin D; IEA:Ensembl.
DR   GO; GO:0060739; P:mesenchymal-epithelial cell signaling involved in prostate gland development; IEA:Ensembl.
DR   GO; GO:0002009; P:morphogenesis of an epithelium; ISO:ComplexPortal.
DR   GO; GO:0007162; P:negative regulation of cell adhesion; IEA:Ensembl.
DR   GO; GO:0007528; P:neuromuscular junction development; ISO:ComplexPortal.
DR   GO; GO:0042475; P:odontogenesis of dentin-containing tooth; IEA:Ensembl.
DR   GO; GO:0001649; P:osteoblast differentiation; HDA:UniProtKB.
DR   GO; GO:0014012; P:peripheral nervous system axon regeneration; ISO:ComplexPortal.
DR   GO; GO:0008284; P:positive regulation of cell population proliferation; IEA:Ensembl.
DR   GO; GO:0010628; P:positive regulation of gene expression; ISO:ComplexPortal.
DR   GO; GO:0060740; P:prostate gland epithelium morphogenesis; IEA:Ensembl.
DR   GO; GO:0030155; P:regulation of cell adhesion; IDA:ComplexPortal.
DR   GO; GO:0001558; P:regulation of cell growth; IDA:ComplexPortal.
DR   GO; GO:0030334; P:regulation of cell migration; NAS:ComplexPortal.
DR   GO; GO:0050727; P:regulation of inflammatory response; ISO:ComplexPortal.
DR   GO; GO:0045471; P:response to ethanol; IEA:Ensembl.
DR   GO; GO:0071774; P:response to fibroblast growth factor; IEA:Ensembl.
DR   GO; GO:0009612; P:response to mechanical stimulus; IEA:Ensembl.
DR   GO; GO:0009611; P:response to wounding; IDA:ComplexPortal.
DR   CDD; cd00054; EGF_CA; 4.
DR   CDD; cd00063; FN3; 14.
DR   CDD; cd00087; FReD; 1.
DR   FunFam; 2.60.40.10:FF:000099; Fibronectin 1; 1.
DR   FunFam; 2.10.25.10:FF:000001; Tenascin C; 14.
DR   FunFam; 2.20.25.10:FF:000006; Tenascin C; 1.
DR   FunFam; 2.60.40.10:FF:000162; Tenascin C; 1.
DR   FunFam; 2.60.40.10:FF:000201; Tenascin C; 1.
DR   FunFam; 2.60.40.10:FF:000207; Tenascin C; 1.
DR   FunFam; 2.60.40.10:FF:000274; Tenascin C; 1.
DR   FunFam; 2.60.40.10:FF:000293; Tenascin C; 1.
DR   FunFam; 2.60.40.10:FF:000346; Tenascin C; 4.
DR   FunFam; 2.60.40.10:FF:000398; Tenascin C; 1.
DR   FunFam; 2.60.40.10:FF:000529; Tenascin C; 1.
DR   FunFam; 2.60.40.10:FF:000610; Tenascin C; 1.
DR   FunFam; 2.60.40.10:FF:000611; Tenascin C; 1.
DR   FunFam; 2.60.40.10:FF:000939; Tenascin C; 1.
DR   FunFam; 3.90.215.10:FF:000001; Tenascin isoform 1; 1.
DR   Gene3D; 2.20.25.10; -; 1.
DR   Gene3D; 3.90.215.10; Gamma Fibrinogen, chain A, domain 1; 1.
DR   Gene3D; 2.60.40.10; Immunoglobulins; 15.
DR   Gene3D; 2.10.25.10; Laminin; 14.
DR   InterPro; IPR050991; ECM_Regulatory_Proteins.
DR   InterPro; IPR000742; EGF.
DR   InterPro; IPR013111; EGF_extracell.
DR   InterPro; IPR041161; EGF_Tenascin.
DR   InterPro; IPR036056; Fibrinogen-like_C.
DR   InterPro; IPR014716; Fibrinogen_a/b/g_C_1.
DR   InterPro; IPR002181; Fibrinogen_a/b/g_C_dom.
DR   InterPro; IPR003961; FN3_dom.
DR   InterPro; IPR036116; FN3_sf.
DR   InterPro; IPR013783; Ig-like_fold.
DR   NCBIfam; NF040941; GGGWT_bact; 1.
DR   PANTHER; PTHR46708; TENASCIN; 1.
DR   PANTHER; PTHR46708:SF1; TENASCIN; 1.
DR   Pfam; PF07974; EGF_2; 1.
DR   Pfam; PF25024; EGF_TEN; 1.
DR   Pfam; PF18720; EGF_Tenascin; 2.
DR   Pfam; PF23106; EGF_Teneurin; 3.
DR   Pfam; PF00147; Fibrinogen_C; 1.
DR   Pfam; PF00041; fn3; 15.
DR   SMART; SM00181; EGF; 14.
DR   SMART; SM00186; FBG; 1.
DR   SMART; SM00060; FN3; 15.
DR   SUPFAM; SSF56496; Fibrinogen C-terminal domain-like; 1.
DR   SUPFAM; SSF49265; Fibronectin type III; 12.
DR   PROSITE; PS00022; EGF_1; 15.
DR   PROSITE; PS01186; EGF_2; 15.
DR   PROSITE; PS50026; EGF_3; 5.
DR   PROSITE; PS51406; FIBRINOGEN_C_2; 1.
DR   PROSITE; PS50853; FN3; 15.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Cell adhesion; Coiled coil; Deafness;
KW   Direct protein sequencing; Disease variant; Disulfide bond;
KW   EGF-like domain; Extracellular matrix; Glycoprotein;
KW   Non-syndromic deafness; Phosphoprotein; Proteoglycan;
KW   Proteomics identification; Reference proteome; Repeat; Secreted; Signal.
FT   SIGNAL          1..22
FT                   /evidence="ECO:0000269|PubMed:1707164"
FT   CHAIN           23..2201
FT                   /note="Tenascin"
FT                   /id="PRO_0000007741"
FT   DOMAIN          174..186
FT                   /note="EGF-like 1; incomplete"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DOMAIN          186..217
FT                   /note="EGF-like 2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DOMAIN          217..248
FT                   /note="EGF-like 3"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DOMAIN          248..280
FT                   /note="EGF-like 4"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DOMAIN          280..311
FT                   /note="EGF-like 5"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DOMAIN          311..342
FT                   /note="EGF-like 6"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DOMAIN          342..373
FT                   /note="EGF-like 7"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DOMAIN          373..404
FT                   /note="EGF-like 8"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DOMAIN          404..435
FT                   /note="EGF-like 9"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DOMAIN          435..466
FT                   /note="EGF-like 10"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DOMAIN          466..497
FT                   /note="EGF-like 11"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DOMAIN          497..528
FT                   /note="EGF-like 12"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DOMAIN          528..559
FT                   /note="EGF-like 13"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DOMAIN          559..590
FT                   /note="EGF-like 14"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DOMAIN          590..621
FT                   /note="EGF-like 15"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DOMAIN          625..715
FT                   /note="Fibronectin type-III 1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00316"
FT   DOMAIN          716..804
FT                   /note="Fibronectin type-III 2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00316"
FT   DOMAIN          805..894
FT                   /note="Fibronectin type-III 3"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00316"
FT   DOMAIN          895..990
FT                   /note="Fibronectin type-III 4"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00316"
FT   DOMAIN          991..1075
FT                   /note="Fibronectin type-III 5"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00316"
FT   DOMAIN          1076..1165
FT                   /note="Fibronectin type-III 6"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00316"
FT   DOMAIN          1167..1256
FT                   /note="Fibronectin type-III 7"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00316"
FT   DOMAIN          1258..1350
FT                   /note="Fibronectin type-III 8"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00316"
FT   DOMAIN          1351..1439
FT                   /note="Fibronectin type-III 9"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00316"
FT   DOMAIN          1440..1531
FT                   /note="Fibronectin type-III 10"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00316"
FT   DOMAIN          1533..1621
FT                   /note="Fibronectin type-III 11"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00316"
FT   DOMAIN          1622..1711
FT                   /note="Fibronectin type-III 12"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00316"
FT   DOMAIN          1712..1801
FT                   /note="Fibronectin type-III 13"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00316"
FT   DOMAIN          1802..1888
FT                   /note="Fibronectin type-III 14"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00316"
FT   DOMAIN          1889..1977
FT                   /note="Fibronectin type-III 15"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00316"
FT   DOMAIN          1975..2190
FT                   /note="Fibrinogen C-terminal"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00739"
FT   COILED          118..145
FT                   /evidence="ECO:0000255"
FT   MOD_RES         65
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:24275569"
FT   MOD_RES         70
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:24275569"
FT   MOD_RES         72
FT                   /note="Phosphoserine; by FAM20C"
FT                   /evidence="ECO:0000269|PubMed:26091039,
FT                   ECO:0007744|PubMed:24275569"
FT   MOD_RES         905
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:24275569"
FT   CARBOHYD        38
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        72
FT                   /note="O-linked (Xyl...) (chondroitin sulfate) serine"
FT                   /evidence="ECO:0000269|PubMed:36213313"
FT   CARBOHYD        166
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        184
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:18780401"
FT   CARBOHYD        327
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        788
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        1018
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:19159218"
FT   CARBOHYD        1034
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:19159218"
FT   CARBOHYD        1079
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:18780401"
FT   CARBOHYD        1093
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:18780401"
FT   CARBOHYD        1119
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        1184
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:19159218"
FT   CARBOHYD        1210
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        1261
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:18780401"
FT   CARBOHYD        1275
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:19159218"
FT   CARBOHYD        1301
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:18780401,
FT                   ECO:0000269|PubMed:19159218"
FT   CARBOHYD        1366
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:19159218"
FT   CARBOHYD        1392
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        1445
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        1455
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        1485
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:18780401,
FT                   ECO:0000269|PubMed:19159218"
FT   CARBOHYD        1534
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        1809
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:16335952"
FT   CARBOHYD        2162
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:18780401"
FT   DISULFID        190..200
FT                   /evidence="ECO:0000250"
FT   DISULFID        194..205
FT                   /evidence="ECO:0000250"
FT   DISULFID        207..216
FT                   /evidence="ECO:0000250"
FT   DISULFID        221..231
FT                   /evidence="ECO:0000250"
FT   DISULFID        225..236
FT                   /evidence="ECO:0000250"
FT   DISULFID        238..247
FT                   /evidence="ECO:0000250"
FT   DISULFID        252..263
FT                   /evidence="ECO:0000250"
FT   DISULFID        256..268
FT                   /evidence="ECO:0000250"
FT   DISULFID        270..279
FT                   /evidence="ECO:0000250"
FT   DISULFID        284..294
FT                   /evidence="ECO:0000250"
FT   DISULFID        288..299
FT                   /evidence="ECO:0000250"
FT   DISULFID        301..310
FT                   /evidence="ECO:0000250"
FT   DISULFID        315..325
FT                   /evidence="ECO:0000250"
FT   DISULFID        319..330
FT                   /evidence="ECO:0000250"
FT   DISULFID        332..341
FT                   /evidence="ECO:0000250"
FT   DISULFID        346..356
FT                   /evidence="ECO:0000250"
FT   DISULFID        350..361
FT                   /evidence="ECO:0000250"
FT   DISULFID        363..372
FT                   /evidence="ECO:0000250"
FT   DISULFID        377..387
FT                   /evidence="ECO:0000250"
FT   DISULFID        381..392
FT                   /evidence="ECO:0000250"
FT   DISULFID        394..403
FT                   /evidence="ECO:0000250"
FT   DISULFID        408..418
FT                   /evidence="ECO:0000250"
FT   DISULFID        412..423
FT                   /evidence="ECO:0000250"
FT   DISULFID        425..434
FT                   /evidence="ECO:0000250"
FT   DISULFID        439..449
FT                   /evidence="ECO:0000250"
FT   DISULFID        443..454
FT                   /evidence="ECO:0000250"
FT   DISULFID        456..465
FT                   /evidence="ECO:0000250"
FT   DISULFID        470..480
FT                   /evidence="ECO:0000250"
FT   DISULFID        474..485
FT                   /evidence="ECO:0000250"
FT   DISULFID        487..496
FT                   /evidence="ECO:0000250"
FT   DISULFID        501..511
FT                   /evidence="ECO:0000250"
FT   DISULFID        505..516
FT                   /evidence="ECO:0000250"
FT   DISULFID        518..527
FT                   /evidence="ECO:0000250"
FT   DISULFID        532..542
FT                   /evidence="ECO:0000250"
FT   DISULFID        536..547
FT                   /evidence="ECO:0000250"
FT   DISULFID        549..558
FT                   /evidence="ECO:0000250"
FT   DISULFID        563..573
FT                   /evidence="ECO:0000250"
FT   DISULFID        567..578
FT                   /evidence="ECO:0000250"
FT   DISULFID        580..589
FT                   /evidence="ECO:0000250"
FT   DISULFID        594..604
FT                   /evidence="ECO:0000250"
FT   DISULFID        598..609
FT                   /evidence="ECO:0000250"
FT   DISULFID        611..620
FT                   /evidence="ECO:0000250"
FT   VAR_SEQ         1072..1708
FT                   /note="Missing (in isoform 6)"
FT                   /evidence="ECO:0000303|PubMed:2466295"
FT                   /id="VSP_001415"
FT   VAR_SEQ         1072..1617
FT                   /note="Missing (in isoform 5)"
FT                   /evidence="ECO:0000303|PubMed:1707164"
FT                   /id="VSP_001414"
FT   VAR_SEQ         1072..1435
FT                   /note="Missing (in isoform 2 and isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:1707164"
FT                   /id="VSP_001412"
FT   VAR_SEQ         1527..1617
FT                   /note="Missing (in isoform 2 and isoform 4)"
FT                   /evidence="ECO:0000303|PubMed:1707164"
FT                   /id="VSP_001413"
FT   VARIANT         213
FT                   /note="G -> S (in dbSNP:rs7020958)"
FT                   /id="VAR_055778"
FT   VARIANT         539
FT                   /note="Q -> R (in dbSNP:rs1757095)"
FT                   /evidence="ECO:0000269|PubMed:1704365,
FT                   ECO:0000269|PubMed:1719530, ECO:0000269|PubMed:2466295"
FT                   /id="VAR_024266"
FT   VARIANT         605
FT                   /note="V -> I (in dbSNP:rs3827816)"
FT                   /id="VAR_024267"
FT   VARIANT         680
FT                   /note="Q -> R (in dbSNP:rs1061494)"
FT                   /evidence="ECO:0000269|PubMed:1707164"
FT                   /id="VAR_024268"
FT   VARIANT         850
FT                   /note="D -> H (in dbSNP:rs3748169)"
FT                   /id="VAR_055779"
FT   VARIANT         1677
FT                   /note="I -> L (in dbSNP:rs2104772)"
FT                   /evidence="ECO:0000269|PubMed:1704365,
FT                   ECO:0000269|PubMed:1719530, ECO:0000269|PubMed:2466295,
FT                   ECO:0000269|PubMed:7531707"
FT                   /id="VAR_060738"
FT   VARIANT         1773
FT                   /note="V -> M (in DFNA56; dbSNP:rs137933052)"
FT                   /evidence="ECO:0000269|PubMed:23936043"
FT                   /id="VAR_070984"
FT   VARIANT         1781
FT                   /note="A -> T (in dbSNP:rs2274750)"
FT                   /id="VAR_020169"
FT   VARIANT         1796
FT                   /note="T -> S (in DFNA56; dbSNP:rs431905513)"
FT                   /evidence="ECO:0000269|PubMed:23936043"
FT                   /id="VAR_070985"
FT   VARIANT         2008
FT                   /note="E -> Q (in dbSNP:rs13321)"
FT                   /evidence="ECO:0000269|PubMed:1704365,
FT                   ECO:0000269|PubMed:1707164, ECO:0000269|PubMed:1719530,
FT                   ECO:0000269|PubMed:2466295, ECO:0000269|PubMed:7531707"
FT                   /id="VAR_014665"
FT   CONFLICT        244
FT                   /note="Missing (in Ref. 2; CAA39628)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        370
FT                   /note="V -> L (in Ref. 1; no nucleotide entry, 3; AAA88083
FT                   and 4; CAA55309)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        1066
FT                   /note="R -> H (in Ref. 1; no nucleotide entry, 3; AAA88083
FT                   and 7; AAA52703)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        1600..1608
FT                   /note="SGFTQGHQT -> LWLHPRASN (in Ref. 1; no nucleotide
FT                   entry, 3; AAA88083 and 7; AAA52703)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        2054
FT                   /note="F -> FLH (in Ref. 1; no nucleotide entry and 3;
FT                   AAA88083)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        2055
FT                   /note="W -> L (in Ref. 7; AAA52703)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        2140..2143
FT                   /note="YKGA -> TRG (in Ref. 2; CAA39628)"
FT                   /evidence="ECO:0000305"
FT   STRAND          807..813
FT                   /evidence="ECO:0007829|PDB:2RB8"
FT   STRAND          819..824
FT                   /evidence="ECO:0007829|PDB:2RB8"
FT   HELIX           827..829
FT                   /evidence="ECO:0007829|PDB:2RBL"
FT   STRAND          831..839
FT                   /evidence="ECO:0007829|PDB:2RB8"
FT   STRAND          842..844
FT                   /evidence="ECO:0007829|PDB:2RBL"
FT   STRAND          847..852
FT                   /evidence="ECO:0007829|PDB:2RB8"
FT   HELIX           853..855
FT                   /evidence="ECO:0007829|PDB:6BRB"
FT   STRAND          857..860
FT                   /evidence="ECO:0007829|PDB:2RB8"
FT   STRAND          868..877
FT                   /evidence="ECO:0007829|PDB:2RB8"
FT   STRAND          885..890
FT                   /evidence="ECO:0007829|PDB:2RB8"
FT   STRAND          1977..1980
FT                   /evidence="ECO:0007829|PDB:8FN8"
FT   HELIX           1984..1989
FT                   /evidence="ECO:0007829|PDB:5R61"
FT   STRAND          1996..2001
FT                   /evidence="ECO:0007829|PDB:5R61"
FT   HELIX           2002..2004
FT                   /evidence="ECO:0007829|PDB:5R61"
FT   STRAND          2008..2015
FT                   /evidence="ECO:0007829|PDB:5R61"
FT   HELIX           2018..2020
FT                   /evidence="ECO:0007829|PDB:5R61"
FT   STRAND          2023..2032
FT                   /evidence="ECO:0007829|PDB:5R61"
FT   HELIX           2040..2045
FT                   /evidence="ECO:0007829|PDB:5R61"
FT   STRAND          2052..2055
FT                   /evidence="ECO:0007829|PDB:5R61"
FT   HELIX           2058..2065
FT                   /evidence="ECO:0007829|PDB:5R61"
FT   STRAND          2070..2078
FT                   /evidence="ECO:0007829|PDB:5R61"
FT   STRAND          2081..2092
FT                   /evidence="ECO:0007829|PDB:5R61"
FT   HELIX           2095..2097
FT                   /evidence="ECO:0007829|PDB:5R61"
FT   STRAND          2101..2110
FT                   /evidence="ECO:0007829|PDB:5R61"
FT   HELIX           2115..2117
FT                   /evidence="ECO:0007829|PDB:5R61"
FT   STRAND          2130..2134
FT                   /evidence="ECO:0007829|PDB:8FNB"
FT   HELIX           2136..2140
FT                   /evidence="ECO:0007829|PDB:5R61"
FT   STRAND          2147..2149
FT                   /evidence="ECO:0007829|PDB:5R61"
FT   STRAND          2151..2153
FT                   /evidence="ECO:0007829|PDB:5R61"
FT   TURN            2163..2165
FT                   /evidence="ECO:0007829|PDB:5R61"
FT   STRAND          2166..2169
FT                   /evidence="ECO:0007829|PDB:5R61"
FT   HELIX           2170..2173
FT                   /evidence="ECO:0007829|PDB:5R61"
FT   STRAND          2180..2188
FT                   /evidence="ECO:0007829|PDB:5R61"
FT   HELIX           2189..2193
FT                   /evidence="ECO:0007829|PDB:5R61"
SQ   SEQUENCE   2201 AA;  240853 MW;  B2BEF378AA6F1D85 CRC64;
     MGAMTQLLAG VFLAFLALAT EGGVLKKVIR HKRQSGVNAT LPEENQPVVF NHVYNIKLPV
     GSQCSVDLES ASGEKDLAPP SEPSESFQEH TVDGENQIVF THRINIPRRA CGCAAAPDVK
     ELLSRLEELE NLVSSLREQC TAGAGCCLQP ATGRLDTRPF CSGRGNFSTE GCGCVCEPGW
     KGPNCSEPEC PGNCHLRGRC IDGQCICDDG FTGEDCSQLA CPSDCNDQGK CVNGVCICFE
     GYAGADCSRE ICPVPCSEEH GTCVDGLCVC HDGFAGDDCN KPLCLNNCYN RGRCVENECV
     CDEGFTGEDC SELICPNDCF DRGRCINGTC YCEEGFTGED CGKPTCPHAC HTQGRCEEGQ
     CVCDEGFAGV DCSEKRCPAD CHNRGRCVDG RCECDDGFTG ADCGELKCPN GCSGHGRCVN
     GQCVCDEGYT GEDCSQLRCP NDCHSRGRCV EGKCVCEQGF KGYDCSDMSC PNDCHQHGRC
     VNGMCVCDDG YTGEDCRDRQ CPRDCSNRGL CVDGQCVCED GFTGPDCAEL SCPNDCHGQG
     RCVNGQCVCH EGFMGKDCKE QRCPSDCHGQ GRCVDGQCIC HEGFTGLDCG QHSCPSDCNN
     LGQCVSGRCI CNEGYSGEDC SEVSPPKDLV VTEVTEETVN LAWDNEMRVT EYLVVYTPTH
     EGGLEMQFRV PGDQTSTIIQ ELEPGVEYFI RVFAILENKK SIPVSARVAT YLPAPEGLKF
     KSIKETSVEV EWDPLDIAFE TWEIIFRNMN KEDEGEITKS LRRPETSYRQ TGLAPGQEYE
     ISLHIVKNNT RGPGLKRVTT TRLDAPSQIE VKDVTDTTAL ITWFKPLAEI DGIELTYGIK
     DVPGDRTTID LTEDENQYSI GNLKPDTEYE VSLISRRGDM SSNPAKETFT TGLDAPRNLR
     RVSQTDNSIT LEWRNGKAAI DSYRIKYAPI SGGDHAEVDV PKSQQATTKT TLTGLRPGTE
     YGIGVSAVKE DKESNPATIN AATELDTPKD LQVSETAETS LTLLWKTPLA KFDRYRLNYS
     LPTGQWVGVQ LPRNTTSYVL RGLEPGQEYN VLLTAEKGRH KSKPARVKAS TEQAPELENL
     TVTEVGWDGL RLNWTAADQA YEHFIIQVQE ANKVEAARNL TVPGSLRAVD IPGLKAATPY
     TVSIYGVIQG YRTPVLSAEA STGETPNLGE VVVAEVGWDA LKLNWTAPEG AYEYFFIQVQ
     EADTVEAAQN LTVPGGLRST DLPGLKAATH YTITIRGVTQ DFSTTPLSVE VLTEEVPDMG
     NLTVTEVSWD ALRLNWTTPD GTYDQFTIQV QEADQVEEAH NLTVPGSLRS MEIPGLRAGT
     PYTVTLHGEV RGHSTRPLAV EVVTEDLPQL GDLAVSEVGW DGLRLNWTAA DNAYEHFVIQ
     VQEVNKVEAA QNLTLPGSLR AVDIPGLEAA TPYRVSIYGV IRGYRTPVLS AEASTAKEPE
     IGNLNVSDIT PESFNLSWMA TDGIFETFTI EIIDSNRLLE TVEYNISGAE RTAHISGLPP
     STDFIVYLSG LAPSIRTKTI SATATTEALP LLENLTISDI NPYGFTVSWM ASENAFDSFL
     VTVVDSGKLL DPQEFTLSGT QRKLELRGLI TGIGYEVMVS GFTQGHQTKP LRAEIVTEAE
     PEVDNLLVSD ATPDGFRLSW TADEGVFDNF VLKIRDTKKQ SEPLEITLLA PERTRDITGL
     REATEYEIEL YGISKGRRSQ TVSAIATTAM GSPKEVIFSD ITENSATVSW RAPTAQVESF
     RITYVPITGG TPSMVTVDGT KTQTRLVKLI PGVEYLVSII AMKGFEESEP VSGSFTTALD
     GPSGLVTANI TDSEALARWQ PAIATVDSYV ISYTGEKVPE ITRTVSGNTV EYALTDLEPA
     TEYTLRIFAE KGPQKSSTIT AKFTTDLDSP RDLTATEVQS ETALLTWRPP RASVTGYLLV
     YESVDGTVKE VIVGPDTTSY SLADLSPSTH YTAKIQALNG PLRSNMIQTI FTTIGLLYPF
     PKDCSQAMLN GDTTSGLYTI YLNGDKAEAL EVFCDMTSDG GGWIVFLRRK NGRENFYQNW
     KAYAAGFGDR REEFWLGLDN LNKITAQGQY ELRVDLRDHG ETAFAVYDKF SVGDAKTRYK
     LKVEGYSGTA GDSMAYHNGR SFSTFDKDTD SAITNCALSY KGAFWYRNCH RVNLMGRYGD
     NNHSQGVNWF HWKGHEHSIQ FAEMKLRPSN FRNLEGRRKR A
//
